Home
    • Plans Blog Contact
    Bluejay Diagnostics Inc logo

    Bluejay Diagnostics Inc

    BJDX
    Last price US$1.05
    Market cap US$1.5m
    12M price change -79.96%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Abbott LaboratoriesABT Industry peer DexCom IncDXCM Industry peer Edwards Lifesciences CorpEW Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Bluejay Diagnostics Inc Overview

    Industry: Medical Devices

    Sector: Healthcare

    Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts. Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Bluejay Diagnostics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Exhibit 99.1 Bluejay Diagnostics Provides First Quarter 2026 Corporate Update ACTON, Mass., May 7, 2026 — Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, to...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing QUARTERLY REPORT Aug 12, 2026 SEC filing CURRENT REPORT May 07, 2026 SEC filing QUARTERLY REPORT May 07, 2026 SEC filing FORM 8-K Mar 06, 2026 SEC filing ANNUAL REPORT Mar 06, 2026 Earnings release PRESS RELEASE, DATED MARCH 6, 2026 Mar 06, 2026 SEC filing QUARTERLY REPORT Nov 07, 2025 SEC filing QUARTERLY REPORT Aug 07, 2025 SEC filing QUARTERLY REPORT May 13, 2025 SEC filing AMENDMENT NO. 1 TO FORM 10-K Apr 29, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Bluejay Diagnostics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Return on Equity

    Score 0.06/5
    Bluejay Diagnostics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bluejay Diag... BJDX US$1.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.37/5
    Bluejay Diagnostics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Bluejay Diag... BJDX US$1.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Leverage

    Score 3.59/5
    Bluejay Diagnostics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Bluejay Diag... BJDX US$1.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Bluejay Diagnostics Inc logo

    Bluejay Diagnostics Inc

    US$1.05

    US$1.5m

    -1.87%

    -79.96%